# Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

> **NCT01207102** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 10 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01207102
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Low enrollment and there is insufficient data to publish.
- **Last updated:** 2014-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01207102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01207102, "Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01207102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*